Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549	
-------------	------	-------	--

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL									
OMB Number: 3235-0287									
Estimated average burden									
hours per response:									

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Shawver Laura				2. Issuer Name and Ticker or Trading Symbol Relay Therapeutics, Inc. [RLAY]						(Ch	Relationship eck all appli X Directo	cable) or	g Pers	10% Ow	mer			
	AY THER	APEUTICS, INC				3. Date of Earliest Transaction (Month/Day/Year) 05/27/2022								Officer below)	(give title		Other (s below)	pecify
399 BINNEY STREET, 2ND FLOOR			4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)							
(Street) CAMBR	IDGE M	Ā	02139											X Form f	iled by Mor	•	orting Person One Repor	
(City)	(S	tate)	(Zip)															
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
Date			2. Transa Date (Month/D	Execution Date,		Code (In	Transaction Disposed Of (D) (Instr. 3, 4 Code (Instr. 5)		ed (A) or tr. 3, 4 and	Benefici	es Form ally (D) o Following (I) (In		n: Direct r Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
						Code	/	Amount	(A) or (D) Price		Transac (Instr. 3	Transaction(s) (Instr. 3 and 4)			Í			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security (Instr. 3) 3. Transaction Date Execution Date, if any (Month/Day/Year)			ransad ode (l	ansaction of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amour of Securities Underlying Derivative Securit (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)				
				C	ode	v			Date Exercisable		opiration ate	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$17.33	05/27/2022			A		41,597		(1)	05	5/26/2032	Common Stock	41,597	\$0.00	41,597	7	D	

Explanation of Responses:

1. This option was granted on May 27, 2022 with respect to 41,597 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date.

Remarks:

/s/ Brian Adams, as Attorney-

in-Fact

05/27/2022

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.